Intensity Therapeutics, Inc.
INTS- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001567264
No open-market purchases or sales by Intensity Therapeutics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $4.79M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Intensity Therapeutics, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 10 | 17 | +7 |
| Shares | 298.4K | 512.6K | +214.2K (+71.8%) |
| Value | $1.19M | $4.39M | +$3.20M (+269.0%) |
New holders (9)
Institutions that held Intensity Therapeutics, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Sapient Capital LLC | 200,000 | $1.71M | 0.04% |
| Vanguard Group Inc | 83,069 | $711.9K | 0.00% |
| Mesirow Financial Investment Management, Inc. | 34,177 | $292.9K | 0.01% |
| HRT Financial LP | 31,907 | $273.0K | 0.00% |
| State Street Corp | 14,500 | $124.3K | 0.00% |
| Qube Research & Technologies Ltd | 6,163 | $52.8K | 0.00% |
| UBS Group AG | 500 | $4.29K | 0.00% |
| Bank of America Corp | 6 | $52 | 0.00% |
| Royal Bank of Canada | 23 | $0 | 0.00% |
Sold out (2)
Institutions that held Intensity Therapeutics, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Millennium Management LLC | 24,822 | $101.3K |
| Tower Research Capital LLC (TRC) | 1,027 | $4.29K |